Patents by Inventor Margaret Chi-Ping Hsu

Margaret Chi-Ping Hsu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Process for the preparation of indazolyl ureas that inhibit Vanilloid subtype 1 (VR1) receptors
    Patent number: 8519186
    Abstract: The present invention relates to a process of preparing indazolyl ureas that are useful as antagonists of the vanilloid receptor subtype 1 (VR1).
    Type: Grant
    Filed: October 28, 2010
    Date of Patent: August 27, 2013
    Assignee: AbbVie Inc.
    Inventors: Kirill A. Lukin, Margaret Chi-Ping Hsu, Dilinie P. Fernando, Brian J. Kotecki, Marvin R. Leanna
  • Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
    Patent number: 8487116
    Abstract: The present invention discloses novel compounds of general formula (I) or a pharmaceutically acceptable salt or prodrug thereof (in which X1-X5, R5-R8b, Z1-Z2 and Ar1 are defined herein), a method for inhibiting the VR1 receptor in mammals using these compounds, a method for controlling pain in mammals, and pharmaceutical compositions including those compounds and a process for making those compounds.
    Type: Grant
    Filed: November 9, 2011
    Date of Patent: July 16, 2013
    Assignee: AbbVie Inc.
    Inventors: Arthur R. Gomtsyan, Erol K. Bayburt, John R. Koenig, Chih-Hung Lee, Robert G. Schmidt, Kirill A. Lukin, Gilles Chambournier, Margaret Chi-Ping Hsu, Robert M. Leanna, Russell D. Cink
  • FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR
    Publication number: 20120190845
    Abstract: The present invention discloses novel compounds of general formula (I) or a pharmaceutically acceptable salt or prodrug thereof (in which X1-X5, R5-R8b, Z1-Z2 and Ar1 are defined herein), a method for inhibiting the VR1 receptor in mammals using these compounds, a method for controlling pain in mammals, and pharmaceutical compositions including those compounds and a process for making those compounds.
    Type: Application
    Filed: November 9, 2011
    Publication date: July 26, 2012
    Inventors: Arthur R. Gomtsyan, Erol K. Bayburt, Chih-Hung Lee, John R. Koenig, Robert G. Schmidt, Kirill A. Lukin, Gilles Chamboumier, Margaret Chi-Ping Hsu, Robert M. Leanna, Russell D. Cink
  • Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
    Patent number: 8071762
    Abstract: The present invention discloses novel compounds of general formula (I) or a pharmaceutically acceptable salt or prodrug thereof (in which X1-X5, R5-R8b, Z1-Z2 and Ar1 are defined herein), a method for inhibiting the VR1 receptor in mammals using these compounds, a method for controlling pain in mammals, and pharmaceutical compositions including those compounds and a process for making those compounds.
    Type: Grant
    Filed: April 30, 2008
    Date of Patent: December 6, 2011
    Assignee: Abbott Laboratories
    Inventors: Arthur R. Gomtsyan, Erol K. Bayburt, Chih-Hung Lee, John R. Koenig, Robert G. Schmidt, Kirill A. Lukin, Gilles Chambournier, Margaret Chi-Ping Hsu, Marvin R. Leanna, Russell D. Cink
  • ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USE THEREOF
    Publication number: 20110144057
    Abstract: The present invention is directed to compounds of formula (I) wherein variables W, X, Y, D, A, n, R1, R2 and R9 are as defined in the description.
    Type: Application
    Filed: February 8, 2011
    Publication date: June 16, 2011
    Applicant: ABBOTT LABORATORIES
    Inventors: Arthur Gomtsyan, Richard J. Perner, John R. Koenig, Margaret Chi-Ping Hsu, Dilinie P. Fernando, Chih-Hung Lee
  • Antagonists of the vanilloid receptor subtype 1 (VR1) and use thereof
    Patent number: 7902236
    Abstract: The present invention is directed to compounds of formula (I) wherein variables W, X, Y, D, A, n, R1, R2 and R9 are as defined in the description.
    Type: Grant
    Filed: February 4, 2009
    Date of Patent: March 8, 2011
    Assignee: Abbott Laboratories
    Inventors: Arthur Gomtsyan, Richard J. Perner, John R. Koenig, Margaret Chi-Ping Hsu, Dilinie P. Fernando, Chih-Hung Lee
  • PROCESS FOR THE PREPARATION OF INDAZOLYL UREAS THAT INHIBIT VANILLOID SUBTYPE 1 (VR1) RECEPTORS
    Publication number: 20110040102
    Abstract: The present invention relates to a process of preparing indazolyl ureas that are useful as antagonists of the vanilloid receptor subtype 1 (VR1).
    Type: Application
    Filed: October 28, 2010
    Publication date: February 17, 2011
    Applicant: ABBOTT LABORATORIES
    Inventors: Kirill A. Lukin, Margaret Chi-Ping Hsu, Dilinie P. Fernando, Brian J. Kotecki, Marvin R. Leanna
  • Process for the preparation of indazolyl ureas that inhibit Vanilloid subtype1 (VR1) receptors
    Patent number: 7847104
    Abstract: The present invention relates to a process of preparing indazolyl ureas that are useful as antagonists of the vanilloid receptor subtype 1 (VR1).
    Type: Grant
    Filed: April 13, 2007
    Date of Patent: December 7, 2010
    Assignee: Abbott Laboratories
    Inventors: Kirill A. Lukin, Margaret Chi-Ping Hsu, Dilinie P. Fernando, Brian J. Kotecki, Marvin R. Leanna
  • ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USE THEREOF
    Publication number: 20100010055
    Abstract: The present invention is directed to compounds of formula (I) wherein variables W, X, Y, D, A, n, R1, R2 and R9 are as defined in the description.
    Type: Application
    Filed: February 4, 2009
    Publication date: January 14, 2010
    Applicant: ABBOTT LABORATORIES
    Inventors: Arthur Gomtsyan, Richard J. Perner, John R. Koenig, Margaret Chi-Ping Hsu, Dilinie P. Fernando, Chih-Hung Lee
  • Antagonists of the vanilloid receptor subtype 1 (VR1) and use thereof
    Patent number: 7504520
    Abstract: The present invention is directed to compounds of formula (I) wherein variables W, X, Y, D, A, n, R1, R2 and R9 are as defined in the description.
    Type: Grant
    Filed: May 10, 2006
    Date of Patent: March 17, 2009
    Assignee: Abbott Laboratories
    Inventors: Arthur Gomtsyan, Richard J. Perner, John R. Koenig, Margaret Chi-Ping Hsu, Dilinie P. Fernando, Chih-Hung Lee
  • FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR
    Publication number: 20080287676
    Abstract: The present invention discloses novel compounds of general formula (I) or a pharmaceutically acceptable salt or prodrug thereof (in which X1-X5, R5-R8b, Z1-Z2 and Ar1 are defined herein), a method for inhibiting the VR1 receptor in mammals using these compounds, a method for controlling pain in mammals, and pharmaceutical compositions including those compounds and a process for making those compounds.
    Type: Application
    Filed: April 30, 2008
    Publication date: November 20, 2008
    Applicant: Abbott Laboratories
    Inventors: Arthur R. Gomtsyan, Erol K. Bayburt, Chih-Hung Lee, John R. Koenig, Robert G. Schmidt, Kirill A. Lukin, Gilles Chambournier, Margaret Chi-Ping Hsu, Robert M. Leanna, Russell D. Cink
  • Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
    Patent number: 7375126
    Abstract: The present invention discloses novel compounds of general formula (I) or a pharmaceutically acceptable salt or prodrug thereof (in which X1-X5, R5-R8b, Z1-Z2 and Ar1 are defined herein), a method for inhibiting the VR1 receptor in mammals using these compounds, a method for controlling pain in mammals, and pharmaceutical compositions including those compounds and a process for making those compounds.
    Type: Grant
    Filed: June 9, 2004
    Date of Patent: May 20, 2008
    Assignee: Abbott Laboratories
    Inventors: Arthur R. Gomtsyan, Erol K. Bayburt, Chih-Hung Lee, John R. Koenig, Robert G. Schmidt, Kirill A. Lukin, Margaret Chi-Ping Hsu, Marvin R. Leanna, Russell D. Cink, Gilles Chambournier
  • Arylation method for the functionalization of O-allyl erythromycin derivatives
    Patent number: 7071314
    Abstract: An efficient arylation technique for use in the synthesis of erythromycin derivatives, involving a modified Heck reaction which employs less than six mole percent of palladium catalyst and no phosphine is disclosed. With this modified Heck reaction, an O-alkenylaryl macrolide can be obtained in a much shorter reaction time than under conventional Heck reaction conditions. The modified Heck reaction can be utilized in a method for phosphine-free arylation of an O-allylic erythromycin derivative, in a method for preparing an O-alkenylaryl erythromycin A derivative, or in a method for preparing a 2?, 4?-hydroxyl protected 6-O-alkenylaryl erythromycin A derivative.
    Type: Grant
    Filed: May 28, 2002
    Date of Patent: July 4, 2006
    Assignee: Abbott Laboratories
    Inventors: Weijang Zhang, Margaret Chi-Ping Hsu, Anthony R. Haight, Matthew John Peterson, Bikshandarkoil A. Narayanan
  • Arylation method for the functionalization of O-allyl erythromycin derivatives
    Publication number: 20030125531
    Abstract: An efficient arylation technique for use in the synthesis of erythromycin derivatives, involving a modified Heck reaction which employs less than six mole percent of palladium catalyst and no phosphine is disclosed. With this modified Heck reaction, an O-alkenylaryl macrolide can be obtained in a much shorter reaction time than under conventional Heck reaction conditions. The modified Heck reaction can be utilized in a method for phosphine-free arylation of an O-allylic erythromycin derivative, in a method for preparing an O-alkenylaryl erythromycin A derivative, or in a method for preparing a 2′,4″-hydroxyl protected 6-O-alkenylaryl erythromycin A derivative.
    Type: Application
    Filed: May 28, 2002
    Publication date: July 3, 2003
    Inventors: Weijang Zhang, Margaret Chi-Ping Hsu, Anthony R. Haight, Matthew John Peterson, Bikshandarkoil A. Narayanan
  • Process for preparing 6-o-substituted erythromycin derivatives
    Patent number: 6437106
    Abstract: In one aspect, the invention relates to a process for preparing 6-O-substituted erythromycin derivatives comprising reacting 2′-substituted and optionally 4″-substituted 9-oxime erythromycin derivatives with an alkylating agent in the presence of a palladium catalyst and phosphine. In another aspect, the invention relates to processes for preparing 6-O-substituted erythromycin ketolides using the palladium-catalyzed alkylation reaction.
    Type: Grant
    Filed: March 3, 2000
    Date of Patent: August 20, 2002
    Assignee: Abbott Laboratories
    Inventors: Eric J. Stoner, Matthew J. Peterson, Yi-Yin Ku, Russell D. Cink, Arthur J. Cooper, Mahendra N. Deshpande, Tim Grieme, Anthony R. Haight, David R. Hill, Margaret Chi-Ping Hsu, Steven A. King, Marvin Robert Leanna, Elaine C. Lee, Maureen A. McLaughlin, Howard E. Morton, James J. Napier, Daniel J. Plata, Prasad S. Raje, Michael Rasmussen, David Riley, Jien-Heh J. Tien, Steven J. Wittenberger